Related references
Note: Only part of the references are listed.Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma
Laurene S. Cheung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity
Masanori Onda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT-301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL)
G. Collins et al.
HEMATOLOGICAL ONCOLOGY (2019)
APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo
Alexander H. Staudacher et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells
Varun Sasidharan Nair et al.
IMMUNOLOGY AND CELL BIOLOGY (2018)
ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies
Francesca Zammarchi et al.
BLOOD (2018)
Fate of Antibody-Drug Conjugates in Cancer Cells
Cecile Chalouni et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Cancer immunotherapy beyond immune checkpoint inhibitors
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Emerging Functions of Regulatory T Cells in Tissue Homeostasis
Amit Sharma et al.
FRONTIERS IN IMMUNOLOGY (2018)
Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine
John A. Hartley et al.
SCIENTIFIC REPORTS (2018)
Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma
Mehdi Hamadani et al.
BLOOD (2018)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Frederick Arce Vargas et al.
IMMUNITY (2017)
Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody-Drug Conjugates
Fu Li et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces anti-tumoral immune responses
Dong Sun Oh et al.
ONCOTARGET (2017)
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Alexander H. Staudacher et al.
BRITISH JOURNAL OF CANCER (2017)
The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer
Michael J. Flynn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies
Jonathan Rios-Doria et al.
CANCER RESEARCH (2017)
Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2016)
ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Michael J. Flynn et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy
Kazuhide Sato et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Antibody-drug conjugates as novel anti-cancer chemotherapeutics
Christina Peters et al.
BIOSCIENCE REPORTS (2015)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Andrea Facciabene et al.
CANCER RESEARCH (2012)
ASSESSING INTERACTIONS FOR FIXED-DOSE DRUG COMBINATIONS IN TUMOR XENOGRAFT STUDIES
Jianrong Wu et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2012)
Targeting regulatory T cells
Christine Menetrier-Caux et al.
TARGETED ONCOLOGY (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells
Guoyan Cheng et al.
IMMUNOLOGICAL REVIEWS (2011)
Share Paper
